Francesco Schettini, MD PhD 🇮🇹🇪🇸🇪🇺
@FrancescoSche20
Followers
1K
Following
6K
Statuses
1K
Medical Oncologist @hospitalclinic, Post-Doc Researcher @IDIBAPS, @EACRnews ambassador, @UniBarcelona #intrinsicsubtypes #biomarkerdevelopment #HER2low.
Barcellona, Spagna
Joined September 2019
Finally out in @ESMO_Open the main findings of my @myESMO #Fellowship research project focused on the identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer. What did we find? A thread 🧵
2
22
84
RT @PTarantinoMD: TNBC treatment in the precision oncology era: -2 cm N0 TNBC: #KN522 -7 cm multi-node+ TNBC: #KN522 -PD-L1 neg: #KN522 -P…
0
35
0
RT @_SEOM: 📰 Manifiesto SEOM “¿Cáncer? ¡NO! TU Cáncer” con motivo hoy del #DiaMundialContraElCáncer #DMCáncer25 ✅ La supervivencia sigue…
0
37
0
Great multidisciplinary meeting in Malta on imaging and theranostics in breast cancer! Thanks to @EANM_NucMed for inviting me. Enriching experience and a great opportunity to discuss with different specialists novel diagnostic and therapeutic opportunities for our patients
0
4
11
Don’t miss the next @EACRnews 2025 Congress for an inspiring interactive meeting covering the latest breakthroughs in cancer research! The abstract submission deadline and travel grant application deadline are just a few weeks away on 06 March 2025! 👇🏻
0
0
3
RT @Vic_albarran: Happy to share our comment review in Nature Communications: “Unlocking the potential of engineered immune cell therapy fo…
0
12
0
RT @curijoey: The combination of tucatinib and trastuzumab (with fulvestrant in HR+ disease) was clinically active in patients with previou…
0
9
0
RT @tangming2005: When NOT to use DESeq2 for RNA-seq analysis? DESeq2 is the gold standard for bulk RNA-seq, but it has limitations. If you…
0
73
0
Wouldn’t say striking, as similar pCR rates have been also observed in some NACT cohorts, yet it is a strategy that might have an impact in the near future. Waiting for EFS. Patients selection will be key.
Simultaneous @NatureMedicine pub of 2 neoadjuvant chemo-IO trials for high-risk ER+ BC: KN-756 & CM-7FL. Both found a striking improvement in pCR rate with IO, with larger Δ if PD-L1+ or low ER. Waiting for EFS data, which will most likely impact practice.
1
3
13
Always good to have more therapeutic options. Though, in the context of HR+/HER2-low it is the worst performing among the 3 approved ADCs (TDXd, SG and DatoDXd)
🚨Kicking off 2025 with a new approval from @FDAOncology FDA Approves Dato-DXd in HR+/HER2– Breast Cancer via @targetedonc @OncoAlert
0
0
2
RT @_SOLTI: 🔴Lanzamos SOLTI Young – Development Program! 🩺 Programa de formación con debates clínicos, ponentes de primer nivel y mucho má…
0
9
0
👇🏻
💥¡Arrancamos con las actividades de #SOLTIYoung! Actividades de formación, mentoría e investigación. Un grupo creado por jóvenes y para jóvenes. Apúntate para estar al día de las novedades: 🔗 🔜 Mañana, lanzaremos el primer programa👀 #beSOLTI
0
0
1
RT @ElisaAgostinett: Now out in Cancer Treatment Reviews a nice review on CAR-T cell therapy for #breastcancer, a still experimental approa…
0
17
0
RT @prat_aleix: Being diagnosed with breast cancer is undoubtedly challenging, but it also presents a unique opportunity to better understa…
0
13
0
¡Muchísimas gracias a la @_SEOM para impulsar la investigación independiente en Oncología! Es verdaderamente un privilegio poder disfrutar de esta ayuda. ¡No veo la hora de empezar! @idibaps @hospitalclinic @CampusClinicUB
1
2
10
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed? Excellent work published in @ESMO_Open by #ChernyNI et al.👇🏻
0
0
3
RT @FilippoMontemu1: Population-health impact of new drugs recommended ...Just finished reading this article with t…
0
3
0
0
0
1
What a way to start 2025!!! I am extremely grateful to the commission that positively evaluated my application. But most of all, thanks thanks thanks to my mentor @prat_aleix for believing in me, sometimes even more than myself 😝 Oh, and happy new year from Sicily to you all
1
1
8
Check out our new study: Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses! @DanieleGeneral4 @EPineda_ONCO @AlbertoEqDS @idibaps @hospitalclinic Open access here👇🏻
0
3
8